mTOR complex inhibition as a novel therapeutic strategy in high grade papillary serous ovarian cancer

被引：0
|
作者：
Musa, F. [1 ]
Alard, A. [2 ]
Blank, S. [1 ]
Pothuri, B. [1 ]
Curtin, J. [1 ]
Schneider, R. [1 ]
机构：
[1] NYU, Sch Med, New York, NY USA
[2] NYU, Sackler Inst Biomed Sci, New York, NY USA
来源：
GYNECOLOGIC ONCOLOGY | 2014年 / 134卷 / 02期
关键词：
D O I：
10.1016/j.ygyno.2014.04.032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
14
引用
收藏
页码：434 / 435
页数：2
相关论文
共 50 条
  • [1] mTOR complex inhibition as a novel therapeutic strategy in high-grade papillary serous ovarian cancer
    Musa, Fernanda
    Alard, Amandine
    David-West, Gizelka
    Giuroiu, Iulia
    Blank, Stephanie
    Pothuri, Bhavana
    Curtin, John P.
    Schneider, Robert
    CANCER RESEARCH, 2014, 74 (19)
  • [2] Dual mTOR inhibition demonstrates antiproliferative and chemosensitizing effects in chemoresistant high-grade papillary serous ovarian cancer
    Musa, F.
    Giuroiu, I.
    Blank, S.
    Korets, S.
    Curtin, J.
    Schneider, R.
    GYNECOLOGIC ONCOLOGY, 2013, 131 (01) : 278 - 278
  • [3] Utilizing colforsin as a novel therapeutic for high grade serous ovarian cancer treatment
    Knarr, Matthew
    Reavis, Hunter
    Mitchell, Marilyn
    Drapkin, Ronny
    CANCER RESEARCH, 2022, 82 (12)
  • [4] Combination of mTOR inhibition and paclitaxel as a personalised strategy in the context of MYC-amplified high-grade serous ovarian cancer
    Martins, F. C.
    Couturier, D-L
    de Santiago, I.
    Vias, M.
    Sanders, D.
    Piskorz, A.
    Hall, J.
    Jimenez-Linan, M.
    Hosking, K.
    Crawford, R.
    Brenton, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [5] FKBPL as a novel therapeutic target and prognostic biomarker in high grade serous ovarian cancer
    Annett, Stephanie
    Moore, Gillian
    Short, Amy
    Moustafa, Neermeen
    Das, Sudipto
    O'Connor, Darran
    McCrudden, Cian
    Kissenpfenning, Adrien
    Nelson, Laura
    Harley, Ian
    Arthur, Ken
    Yakkundi, Anita
    McCluggage, Glen
    Marshall, Andrea
    Furlong, Fiona
    McCarthy, Helen O.
    Cotton, Graham
    Harrison, Timothy
    McClements, Lana
    Robson, Tracy
    CANCER RESEARCH, 2018, 78 (13)
  • [6] Identification of novel therapeutic targets to overcome chemoresistance in high-grade serous ovarian cancer
    Christie, E.
    Huang, C.
    Zhang, V.
    Cowley, K.
    Simpson, K.
    Wang, G.
    Cao, P.
    Wiedemeyer, W.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S113 - S113
  • [7] Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer
    Moran-Jones, Kim
    Gloss, Brian S.
    Murali, Rajmohan
    Chang, David K.
    Colvin, Emily K.
    Jones, Marc D.
    Yuen, Samuel
    Howell, Viive M.
    Brown, Laura M.
    Wong, Carol W.
    Spong, Suzanne M.
    Scarlett, Christopher J.
    Hacker, Neville F.
    Ghosh, Sue
    Mok, Samuel C.
    Birrer, Michael J.
    Samimi, Goli
    ONCOTARGET, 2015, 6 (42) : 44551 - 44562
  • [8] Static and microfluidic platforms for novel therapeutic testing in high-grade serous ovarian cancer
    Cavarzerani, Enrico
    Saorin, Gloria
    Mauceri, Matteo
    Caligiuri, Isabella
    Bartoletti, Michele
    Canzonieri, Vincenzo
    Rizzolio, Flavio
    CANCER RESEARCH, 2024, 84 (07)
  • [9] Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer
    Andorfer, Peter
    Heuwieser, Alexander
    Heinzel, Andreas
    Lukas, Arno
    Mayer, Bernd
    Perco, Paul
    BMC SYSTEMS BIOLOGY, 2016, 10
  • [10] Connective tissue growth factor (CTGF) as a novel therapeutic target in high grade serous ovarian cancer
    Moran-Jones, Kim
    Murali, Rajmohan
    Chang, David K.
    Wong, Carol W.
    Spong, Suzanne M.
    Hacker, Neville F.
    Mok, Samuel C.
    Birrer, Michael J.
    Samimi, Goli
    CLINICAL CANCER RESEARCH, 2013, 19
12345